FDA Brief

Warning letters Drugs

FDA warning letter to

C&T Dream Co., Ltd.

High riskIssued Apr 11, 2024Posted Apr 16, 2024Center for Drug Evaluation and Research | CDER

C&T Dream failed CGMP (current good manufacturing practice) for its over-the-counter Dry Skin Healing Ointment, including identity testing and process validation.

What happened

FDA inspected the drug manufacturing facility from November 6 to 10, 2023. Investigators found no adequate identity testing of incoming components, including glycerin, for diethylene glycol or ethylene glycol; no adequate process validation; and water damage, a mold-like substance, and an active ceiling leak in the research and development building. FDA said the firm did not respond to the inspection findings form (Form FDA 483) with corrective actions and cited similar observations from a 2017 inspection.

What FDA found

  1. The firm did not test each incoming component lot for identity, including glycerin, to detect diethylene glycol or ethylene glycol contamination.

    21 CFR 211.84(d)(1)
  2. The firm did not adequately validate its production and process controls to show it can consistently manufacture the OTC drug with defined quality.

    21 CFR 211.100(a)
  3. The firm did not keep its research and development building in good repair; FDA saw water damage, a mold-like substance, and an active ceiling leak.

    21 CFR 211.58

What FDA wants

FDA tells the firm to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence. FDA also asks the firm to clarify whether it will resume U.S. drug manufacturing and to notify FDA before resuming or moving operations, and recommends a qualified CGMP consultant.

Who should pay attention

  • brands that buy OTC topical drug products from this contract manufacturer
  • distributors and importers of foreign-made OTC drugs
  • suppliers of glycerin and other high-risk drug components

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk